FDA Accepts for Review Libtayo (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC

TARRYTOWN, N.Y., Jan. 19, 2022. Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for PD-1 inhibitor Libtayo...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials